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ABSTRACT 
This work investigated the impact of formulation including in vitro release profile, repeated 
dosing, and nail poration on the ex vivo nail delivery performance of antifungal formulations. 
Chitosan coated and uncoated tioconazole-loaded nanocapsules and a nano-based film-forming 
vehicle were assessed via in vitro release and in vitro permeation tests using an artificial membrane 
and human nail clippings, respectively. The later involved single and daily dosing experiments 
with intact and porated nails. Additional experiments with Nile Red-loaded formulations evaluated 
the depth of penetration of the fluorescent marker into the nail by laser scanning confocal 
microscopy. The nanocapsule formulations prolonged release of tioconazole for longer than the 
control solutions and this ability was related to an enhanced nail penetration of the drug. Further, 
the new film-forming formulation delivered its drug payload more efficiently than a marketed 
product. Daily dosing of the formulations doubled the amount of drug recovered from the nails. 
Porating the nails enhanced tioconazole delivery in single dose experiments only. The depth of 
penetration of Nile Red into the nails clippings ranged between 90-160 µm. This research suggests 
that ensuring prolonged release of a drug is fundamental to develop efficacious topical nail 
formulations.  
KEYWORDS: Nail; nanocapsules; tioconazole; onychomycosis; multiple dosing; poration. 
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1. Introduction 
Onychomycosis or ungual fungal infection causes approximately 50% of the diseases of the nail 
yet its treatment is far from satisfactory (Baran and Kaoukhov, 2005). Systemic therapies require 
long periods of treatment and have potential for drug interactions and side effects (Baran et al., 
2008). These limitations could be alleviated by using topical therapies but unfortunately, the 
effectiveness of topical products to treat onychomycosis is rather limited (Crawford and Hollis, 
2007). It is believed that topical therapies fail to provide and maintain antifungal therapeutic levels 
at the target site including the nail bed due the low permeability of actives across the nail plate 
(Hao and Li, 2013, Shivakumar et al., 2013). Consequently, several strategies have been explored 
to improve ungual drug delivery including chemical and physical enhancement (iontophoresis and 
lasers) methods (Delgado-Charro, 2012, Saner et al., 2014, Shivakumar et al., 2013).  
In addition, most marketed nail products are lacquers based on organic solvents (Saner et al., 
2014), a formulation approach with significant limitations. When these lacquers are applied onto 
the nail plate, the organic solvents evaporate quickly, leaving a residue of crystallized drug unable 
to partition into and to diffuse through the nail plate (Hao and Li, 2013). Thus, an additional 
strategy to improve ungual drug delivery is to formulate vehicles that prevent crystallization of the 
antifungal and ensure its release and delivery over long periods of time. This capability can be 
assessed easily through in vitro release tests (IVRT) performed with artificial membranes across 
which the drug is relatively permeable as, under these conditions, the overall process is primarily 
rate-limited by drug release from the formulation.  
Nano-size formulations present advantages for topical skin delivery; they can ensure stability of 
actives and act as reservoirs that provide extended drug delivery (Contri et al., 2011, Firooz et al., 
2015). Recently, Flores et al., (2017) prepared a series of tioconazole-loaded cationic polymeric 
nanocapsules based on Pullulan, a water-soluble polysaccharide with film-forming properties. The 
new formulations containing 1 mg/mL of the drug showed similar antifungal efficacy than Trosid®, 
a marketed product containing 283 mg/mL of the drug. Dialysis studies demonstrated the slow 
release of tioconazole from the new formulations but neither the in vitro release nor the nail 
permeation profiles of the drug where characterized and compared to those provided by a marketed 
product. Thus, a first aim of this work was to investigate the potential relationship between the in 
vitro release (IVRT) and the ex vivo delivery performance (IVPT) for the nanocapsule formulations 
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and the commercial product above. More specifically, this work investigated whether the 
antifungal performance of the new formulations (Flores et al., 2017) observed could be explained, 
at least partially, by their ability to provide extended release as compared to the marketed lacquer. 
In contrast with the skin, nails lack the appendages and furrows where nanostructures typically 
localize after application of topical products (Alvarez-Román et al., 2004). Thus, it has been 
proposed that nails could be porated mechanically to provide sequestration sites for nanoparticles. 
Chiu et al., (2015) used a skin poration device (Dermaroller®) to introduce a nanoparticle-based 
formulation into the nails. Sustained release of Nile Red from the nanoparticles was possible and 
diffusion was observed deeper into the nail as compared to non-porated nails. Further 
corroboration was obtained using TAPP-labelled nanoparticles containing octylmethoxy 
cinnamate; two-photon fluorescence and stimulated Raman scattering imaging were used to assess 
the disposition of both the particles and the marker (Chiu et al., 2015). The results suggested that 
topical bioavailability of antifungals could be improved by combining nail poration and 
formulation approaches. Thus, a second aim of this work was to test this novel approach with an 
antifungal drug and investigate whether tioconazole ungual delivery by the new nanocapsule 
formulations could be enhanced further by nail poration.  
To these aims, tioconazole-loaded nanocapsules suspensions were prepared and included in a 
film-forming formulation as previously described (Flores et al., 2017). The performance of these 
formulations and of Trosid® was characterized through in vitro release tests (IVRT) and in vitro 
permeation tests (IVPT). Additionally, the effect of nail poration as an adjuvant tool to improve 
nail delivery was explored. Another series of matching experiments using Nile Red and confocal 
microscopy investigated the depth and pathways of penetration of the fluorescent marker into the 
nail plate when delivered from the new vehicles. Finally, the use of different IVPT experimental 
(Franz diffusion cells versus in-line cells) and dosing (single versus multiple) approaches were 
tested. 
2. Material and Methods 
2.1 Chemicals 
Tioconazole (TIO) was bought from Pharma Nostra (São Paulo, Brazil) and Trosid® (Pfizer, 
Madrid, Spain) was purchased from a community pharmacy. The polymers Poli(Ɛ-caprolactone) 
(MW=70,000-90,000) and chitosan were acquired from Sigma-Aldrich (São Paulo, Brazil). Nile 
 5
Red (NR) analytical grade was from Sigma-Aldrich (Gillingham, United Kingdom), Lipoid® S75 
from Lipid Ingredients & Technologies (São Paulo, Brazil) and Polysorbate 80, medium chain 
triglycerides and cetostearyl alcohol were from Delaware (Porto Alegre, Brazil). Pullulan was 
kindly donated by Dinaco (Rio de Janeiro, Brazil). Methanol was supplied from Tedia (São Paulo, 
Brazil) and methanol HPLC grade was from VWR Pro-Labo, France. All other chemicals and 
solvents including ethanol were of pharmaceutical grade and were used as received.  
2.2 Nail clippings 
The collection of human nail clippings was approved by REACH or ethics committee for the 
School for Health of the University of Bath (REACH; EP 11/12 115). Nail clippings at least 8 mm 
long were donated by healthy volunteers after providing written informed consent. The nail 
clippings were washed with deionized water, dried with absorbent paper and frozen (-20°C) until 
use. The thickness of the nail clippings ranged between 350-490 m. Micropores were done using 
a dermaroller (Infinitive Beauty®, Birmingham, United Kingdom) with 250 μm long titanium 
needles, which was applied on the dorsal surface of the nail by rolling it back and forth a total of 
10 times.  
2.3 Preparation of formulations 
Aqueous suspensions containing tioconazole-loaded polymeric nanocapsules (TIO-NC) and 
tioconazole-loaded cationic polymeric nanocapsules (TIO-C-NC) were prepared by interfacial 
deposition of pre-formed polymer (Fessi et al., 1989) as previously described (Flores et al., 2017). 
Briefly, an organic phase containing 100 mg of Poly(Ɛ-caprolactone), 10 mg of tioconazole, 0.33 
mL of medium chain triglycerides and 25 mL of acetone was magnetically stirred at 40 °C for one 
hour. Next, 5 mL of an ethanolic solution of Lipoid® S75 (6 mg/mL) were added. This organic 
phase was injected into an aqueous phase (50 mL) containing 76.8 mg of polysorbate 80. The 
mixture was submitted to evaporation under reduced pressure and to a final volume of 10 mL; the 
final concentration of drug was 1.0 mg/mL. In the case of the TIO-C-NC the final volume was 
adjusted to 9 mL and then, 1 mL of a chitosan aqueous solution (1% of chitosan in 0.5% glacial 
acid acetic) was added to the mixture. The lacquer, film forming formulation (L-TIO-C-NC) was 
prepared by adding under magnetic stirring 9 mL of the TIO-C-NC formulation to 1 mL of an 
ethanol solution containing 100 mg of cetoestearyl alcohol. Finally, 100 mg of pullulan were added 
to the mixture. The final volume was adjusted through evaporation so the drug concentration would 
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be 1mg/mL. 
 Nile Red loaded nanocapsules (NR-NC) and cationic polymeric nanocapsules (NR-C-NC) were 
prepared replacing tioconazole (logP=5.3; MW=387.7 Da; pKa=6.5) for Nile Red, (logP=5.0; 
MW=318.3 Da; pKa=4.8). The preparation method above was followed but the organic phase 
contained NR (1.5 mg) instead of tioconazole and the final concentration of marker in both (NR-
C-NC and NR-NC) formulations was 0.15 mg/mL. In the case of the NR-C-NC the final volume 
was adjusted to 9 mL and then, 1 mL of the chitosan solution was added. The formulations 
containing Nile Red were filtered (0.45 μm nylon filters, Whatman, Maidstone, UK).  
2.4 Characterization of tioconazole and Nile Red loaded formulations 
The mean particle size and the polydispersity index were determined (n=3) by photon correlation 
spectroscopy (ZetasizerNano ZS, Malvern Instruments, United Kingdom) after dilution (x500) of 
each formulation with purified water. The zeta potential of the TIO-NC and TIO-C-NC 
formulations was determined (n=3) from the eletrophoretic mobility of particles (ZetasizerNano 
ZS, Malvern Instruments, UK) after sample dilution (x500) in 10 mM NaCl previously filtered 
(0.45 μm nylon filters, Whatman, Maidstone, UK).  
Tioconazole content was assessed by HPLC as previously described (Flores et al., 2017). Briefly, 
100 µL of the TIO-NC, TIO-C-NC and L-TIO-C-NC formulations were diluted in 10 mL methanol 
and the mixture ultra-sonicated for 30 min. The samples were filtered and 20 µL of the filtrate was 
analysed for tioconazole content by HPLC (Agilent, 1260) following a method previously 
validated (Härter et al., 2004). The concentration of NR in the nanocapsules (NR-NC and NR-C-
NC) suspension was measured by HPLC-with fluorescence detection (Dionex, Sunnyvale, CA); 
the excitation and emission wavelengths were 559 nm and 630 nm, respectively. The method (Chiu  
et al., 2015) used a HiQ sil C18W 250x4.6 mm (KYA Tech, Tokyo, Japan) column a 
methanol:water (95:5) mobile phase, a flow rate of 1 mL/min, and a 20 µL injection volume. 
Encapsulation efficiency was analysed by the ultrafiltration-centrifugation technique as 
previously described (Flores et al., 2017). Briefly, 300 µL of either the TIO-NC or TIO-C-NC 
formulations were submitted to ultrafiltration-centrifugation (Ultracel®, 10K membrane 
regenerated cellulose Millipore, Germany) at 5000 rpm for 7 min at 25 °C to separate the 
unassociated (free) tioconazole from the nanocapsules. The ultra-filtrated was analysed by liquid 
chromatography using the same method described above.  
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2.5 Tioconazole and Nile Red control formulations: 
A series of control formulations were prepared: TIO-S was a 50:50 ethanol:water control 
solution containing 1 mg/mL tioconazole. A film-forming control formulation without 
nanocapsules (L-TIO) was prepared by adding 9 mL of TIO-S to 1 mL of ethanol containing 0.1 
g of cetoestearyl and final addition of 0.1 g of pullulan to the mixture. The commercial formulation 
Trosid® nail solution containing 28% (283 mg/mL) of tioconazole and the excipients undecylenic 
acid and ethyl acetate (BNF, 2016, eMC, 2016) was used as a comparator in multiple dose IVPT 
studies. Finally, a 0.15 mg/mL Nile Red solution in 50:50 v/v ethanol:water was used also as a 
control (NR-S). 
2.6 Tioconazole and Nile Red in vitro release tests (IVRT)  
IVRT (n=3) were performed using vertical Franz diffusion cells (3.14 cm2; PermeGear Inc., 
Bethlehem, PA) and a silicone membrane (75 µm thick, Dow-Corning, Coventry, UK). 0.5 mL of 
TIO-NC, TIO-C-NC and the control TIO-S were applied resulting in a 0.16 mg/cm2 area-
normalized dose of tioconazole. 100 L of the formulations L-TIO-C-NC, L-TIO and 3 mg 
Trosid® were applied corresponding to 0.032 mg/cm2 and 0.26 mg/cm2 normalized doses, 
respectively. The donor chamber was covered with Parafilm® in all cases. The receptor solution 
(~10 mL) was phosphate buffer saline (pH 7.4) with 0.5% of polysorbate 80 and was stirred. The 
whole ensemble was incubated at 32 °C. At predetermined periods, 0.5 mL of receptor medium 
were sampled and replaced by fresh PBS. The amount of tioconazole in the receptor samples was 
quantified by HPLC.  
IVRT with Nile Red formulations were conducted to characterize the release profile of the 
fluorescent marker from the formulations NR-NC, NR-C-NC, NR-S and L-NR-C-NC later used 
in IVPT and LSCM imaging. These were conducted as above but the area-normalized dose (24 
g/cm2) applied of Nile Red was lower. 
2.7 Tioconazole in vitro nail permeation tests (IVPT) 
Several IVPT protocols (Franz versus in-line cells; single versus multiple dosing, and intact 
versus porated nail) were carried out to characterize the performance of the formulations in 
delivering tioconazole to the nail plate. Human nail tips (at least 8 mm long) from healthy donors 
were used in all cases; the nail clippings were soaked in deionized water for 30 min prior the 
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experiments, to provide them with sufficient flexibility to be fitted in the nail. All experiments 
lasted 7 days and were performed in triplicate. In all cases; the nail tips were removed from the 
adaptor at the end and rinsed with deionized water. The area of the nail exposed to the formulations 
was cut into small pieces and tioconazole was extracted by shaking the fragments with 1 mL of 
methanol: water (80:20) for 7 days. The extracts were analysed for tioconazole by HPLC.  
2.7.1 Intact nails - single dose - Franz cells: Intact (non-porated) nail tips were placed in a nail 
adapter (PermeGear Inc., Bethlehem, PA, diffusion area=0.2 cm2) which was sandwiched between 
the donor and receptor compartments of vertical Franz diffusion cells. The ventral surface of the 
nail faced the receptor chamber which was filled with ~7.5 mL of receiver solution (pH 7.4 PBS 
+ 0.5% of Tween 80). 1 mL of the formulations TIO-NC, TIO-C-NC and TIO-S were applied to 
the nail dorsal surface once, on the first day of the experiment. The equivalent normalized dose 
was 5 mg/cm2 of tioconazole. The donor chamber was covered with Parafilm® to avoid 
evaporation. A sample (0.6 mL) of receptor chamber was taken every 24 h and replaced with fresh 
medium. The ensemble was kept at 32 °C in an incubator (Heraeus, Kendro Laboratory Products, 
Germany) under magnetic stirring.    
2.7.2 Intact nails- single dose - In-line cells: To facilitate detection of tioconazole in the receptor, 
a second series of experiments with non-porated nails used in-line cells (area: 0.2 cm2; PermeGear 
Inc., Bethlehem, PA,) provided with a smaller (~0.5 mL) receptor compartment. 0.3 mL of the 
TIO-NC, TIO-C-NC and TIO-S formulations were applied once at the beginning of the 
experiment; the normalized dose of tioconazole was 1.5 mg/cm2. The donor chamber was closed 
with Parafilm® and the receptor medium was the same as before. Non-occluded conditions and a 
smaller dose (0.1 mL formulation; 0.5 mg/cm2 of tioconazole) were used for the film-forming 
formulation (L-TIO-C-NC) as to mimic a practical use of the formulation. The ensemble was kept 
at 32 °C in an incubator (Heraeus, Kendro Laboratory Products, Germany) and shaken in a 
horizontal shaker (brand) for 7 days. Receptor samples (0.4 mL) were collected every 24 h and 
replaced by fresh medium.  
2.7.3 Intact nails - daily dosing - In-line cells: This protocol used in-line cells as above but the 
formulations (TIO-NC, TIO-C-NC, TIO-S, L-TIO-C-NC) were applied once daily (i.e., every 24 
h) for 7 days. The normalized doses of tioconazole were 1.5 mg/cm2 for TIO-NC, TIO-C-NC and 
TIO-S and 0.5 mg/cm2 for L-TIO-C-NC as above. In the case of Trosid®, the formulation was 
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applied with a brush twice a day as described in the patient information leaflet. To estimate the 
dose applied three nail clippings were weighed before and after application of Trosid®. It was 
estimated that application with the brush deposited 3 mg of the lacquer (or 0.85 mg of TIO or 4.25 
mg/cm2, assuming a density of 1 g/mL for the product). In all cases, a cotton bud imbibed in water 
was passed three times over the nail sample before applying a subsequent dose to remove residues 
from previous doses.  
2.7.4 Porated nails -single and daily dosing– In line cells: In-line cells experiments with single 
and daily application of the formulations TIO-NC, TIO-C-NC and L-TIO-C-NC were repeated as 
described above but using porated nails. 
2.8 Nile Red in vitro permeation tests (IVPT) 
The depth of penetration of Nile Red into intact and porated nail clippings when delivered from 
the formulations NR-NC, NR-C-NC, NR-S and L-NR-C-NC was investigated using LSCM (Dutet 
and Delgado-Charro, 2012). The experiments mirrored the Franz cells protocol described above. 
0.5 mL (0.38 mg/cm2 normalized dose of NR) of the formulations were applied to the dorsal nail 
and the donor chambers were covered with Parafilm® except when the film-forming L-NR-C-NC 
was used (to mimic a practical application). Three different dosing strategies were investigated: 
(1) single application (NR-C-NC, NR-NC and NR-S) to intact nails; (2) daily application (all 
formulations above) to intact nails and (3) daily application (all formulations above) to porated 
nails. At the end of the 7 days long experiments (n=3) the nail clippings were removed from the 
adaptor and rinsed with deionized water. 1 rectangular piece for dorsal imaging (in which case 
images were taken on 3 different regions) and 3 thin slices for tranversal images were cut from the 
area exposed to the formulation.  
LSCM imaging was carried out in an LSCM 510Meta inverted laser (HeNe, 543 nm) scanning 
microscope (Carl Zeiss, Jena, Germany). An EC Plan-Neo 40x/1.3 M27 oil objective was used for 
the dorsal images of the nail and imaging sections were captured every 2 µm. The nail specimens 
for transversal imaging were placed so the cross-section was a few microns from the objective 
(Plan-Apochomath 10x/0.45 M27). In the case of transversal imaging, 10 measurements per piece 
of nail were done using the “specify” and “plot profile” plugins in ImageJ software (US National 
Institutes and Health, United States of America). Both reflectance and optical images were 
captured simultaneously and processed with aid of ImageJ software.  
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2.9 Data and statistical analysis 
 All experiments were carried out in triplicate and the results are expressed as mean ± standard 
deviation. In the case of in vitro release data, the ratios of the percentage released at two-time 
points [%R24h/%R2h] and [%R24h/%R10h] were used to compare the efficiency of the formulations 
in releasing tioconazole during the 2–24 hours and the 10-24 hours intervals, respectively. For 
example, a [%R24h/%R10h] = 1 indicated that no tioconazole was released between 10 and 24 hours, 
whereas a [%R24h/%R10h] = 2 indicated that the amount of tioconazole released had doubled in the 
interval considered. In the case of IVPT data, the total amount of tioconazole recovered from each 
nail (TIO-Rec), the apparent concentration of tioconazole in the nail (TIO/nail) and the percentage 
delivered to the nail with respect the total dose applied (DRec%) were estimated.  
Comparisons among formulations were done by one-way ANOVAs followed by Bonferroni’s 
multiple comparison tests; the effect of poration and of multiple dosing for each formulation was 
assessed trough t-tests. The level of statistical significance was established at p≤0.05.  
3. Results and Discussion 
3.1 Preparation and preliminary characterization of the tioconazole-loaded nanocapsule 
formulations  
The tioconazole-loaded polymeric nanocapsule aqueous suspensions (TIO-NC, TIO-C-NC) and 
the lacquer, film-forming formulation (L-TIO-C-NC) more suitable for practical use, were 
prepared and characterized as previously described (Flores et al., 2017). Table 1 shows some 
properties of the formulations prepared; a complete description of the formulation can be found 
elsewhere (Flores et al., 2017). The average tioconazole content (0.97±0.02 mg/mL) for all 
formulations was close to the theoretical value (1 mg/mL) and the association efficiencies were 
close to 100%. The stability of the formulations was demonstrated for at least 30 days. The mean 
particle size determined by photon correlation spectroscopy was in the nanometric range (< 200 
nm) for TIO and NR nanoformulations and the values of polydispersity indexes were <0.20 in all 
cases (Table 1). The zeta potential values were negative for TIO-NC and NR-NC formulations and 
positive for the TIO-C-NC and NR-C-NC formulations, reflecting the addition of the chitosan to 
the latter.  
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3.2 In Vitro Release Tests (IVRT) results  
IVRT were done to assess the capacity of the formulations to sustain delivery of the antifungal. 
Silicone membranes were chosen because of (a) their ability to limit water transfer from the 
receptor into the donor compartment, an important difference with dialysis membranes used in 
previous work (Flores et al., 2017) and (b) the much lesser resistance offered to drug diffusion 
compared to the nail plate. IVRT results obtained with the nanocapsule-based and control 
formulations are summarized in Fig.1.A-B. As expected, the control solution TIO-S provided the 
fastest release followed by the film-forming control (without nanocapsules) formulation L-TIO, 
the commercial product and then, the nanocapsule-based formulations TIO-NC and TIO-C-NC. 
The slowest release was provided by the film-forming formulation containing nanocapsules L-
TIO-C-NC.   
  Overall, the IVRT data suggested that both the incorporation into nanocapsules and use of the 
film-forming lacquer delayed release of tioconazole. In addition, the release pattern (Fig.1.A) was 
different for the vehicles tested; a plateau was reached at 10 hours for the control solutions (TIO-
S, and L-TIO) but not for the nano-based formulations. To assess the capacity of the formulations 
to sustain release of tioconazole after 2 and 10 hours, the ratio of the percentage released at two-
time points [%R24h/%R2h] and [%R24h/%R10h] were used (Fig.1.B). The ratios [%R24h/%R2h] and 
[%R24h/%R10h] for two of the experimental formulations (TIO-C-NC and L-TIO-C-NC) were 
significantly higher (p<0.01) than for the control solution TIO-S and Trosid®. No statistically 
significant differences were found among the nano-based formulations. The values of 
[%R24h/%R10h] for L-TIO-C-NC (1.80.3) and TIO-C-NC (1.80.2) indicate that these two 
vehicles released TIO for longer periods than the commercial nail lacquer (1.20.09). The 
[%R24h/%R10h] ratios for the controls TIO-S and L-TIO were 1.10.04 and 1.10.02 respectively, 
suggesting little tioconazole release after 10 hours (Fig.1.A). The release profile provided by 
Trosid® was closer to that provided by the control solutions (TIO-S and L-TIO) which is consistent 
with the formulae described in the electronic Medicines Compendium (eMC). 
3.3 In vitro permeation tests (IVPT) results  
Table 2 summarizes the results of single and multiple dosing experiments with intact and porated 
nails. Preliminary experiments comparing Franz and in-line cells resulted in relatively similar 
amounts of drug recovered from the nail clippings (TIO-Rec). A higher normalized dose was 
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applied in the case of Franz cells so the percentage of dose recovered (DR%) was greater for in-
line cells. Given that the smaller receptor of in-line cells facilitated quantification, this set-up was 
retained for subsequent experiments.  
Tioconazole was easily extracted from nail clippings at the end of all experiments but no drug 
was quantified in the receptor in any case. The normalized amount of drug extracted from the 
samples (TIO/nail; Table 2), granting it represents an average concentration across the nail, 
compared very favourably to minimum inhibitory concentration (MIC) values (4.6 µg/mL for C. 
albicans, 0.5 µg/mL for T. rubrum and 0.1 µg/mL for T. mentagrophytes) (Jevons et al., 1979). 
Single dose experiments with intact nail clippings suggested that inclusion of tioconazole in 
nanocapsule-based vehicles was a valuable strategy (Table 2). Despite the smaller normalized dose 
of drug applied with the film-forming L-TIO-C-NC, this formulation delivered the greatest amount 
of drug to the nail clippings (TIO-Rec) and was the most efficient in delivering its cargo (DRec%). 
Nail poration as a potential adjuvant enhancement technique was tested next; this strategy 
increased delivery of tioconazole (TIO-Rec and DRec%) although the effect was only significant 
(p<0.05) for the TIO-C-NC and the L-TIO-C-NC vehicles, in which case the performance 
approximately doubled (Table 2). These results are consistent with those reported by Chiu (2015) 
who showed that nail poration created “sequestration sites” for nanoparticles from which the 
encapsulated compounds (octyl methoxycinnamate and Nile Red) were delivered. Again, the film-
forming L-TIO-C-NC provided the best results with porated nails, as nearly 7% of the cargo were 
recovered from the nail clippings compared to 1-1.5% delivered by the other nanocapsules 
suspensions.  
In the experiments above, the formulations were applied at the beginning of the experiments and 
left on place for the complete length (7 days) of the experiments. This set-up, like most published 
ungual drug delivery work, provides results following a single dose application. However, this 
approach hardly represents the real-world scenario in which patients apply lacquers once or twice 
daily. In addition, information about drug penetration into the nail after repeated doses is required 
for establishing a dosing regimen that balances efficiency of delivery with patients’ convenience. 
For example, Hui et al., (2017) used a multiple dosing in vitro study to investigate whether the nail 
concentration of a new compound exceeded the required MIC after 14 days. Thus, matching IVPT, 
in which the same formulations were applied daily, were performed to investigate tioconazole 
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delivery to the nail in a simulated practical application scenario. These studies involved an 
additional control, the marketed formulation, Trosid® which was applied twice daily as indicated 
in the patient information leaflet. Multiple dosing increased significantly (p<0.05) the amount of 
tioconazole delivered by the nano-based formulations to intact nail clippings but the moderate 
increase (1.5-2.5 fold) observed was not proportional to the 7-fold greater cumulative dose applied 
(Table 2). This is shown by the significantly (p<0.05) decreased percentage of tioconazole 
delivered with respect to the cumulative dose applied (DRec%). In the case of porated nails, the 
amount recovered after multiple and single dosing was only significantly different (p<0.05) for the 
TIO-C-NC vehicle and DRec% was decreased in all cases. It is possible, therefore, that the first, 
single dose continued to provide TIO delivery over several days so replacement by subsequent 
doses offered a moderate benefit. This is indeed possible, as the formulations were far from drug 
depletion at the end of the experiments (Table 2) and is consistent with the small differences 
observed when a higher normalized dose (Franz cell set up) was used. From a practical point of 
view, these findings suggest that daily dosing schedules with the new formulations could encumber 
patient (decreasing adherence) without offering significantly improved efficacy. Instead, a more 
convenient schedule (i.e., every two or three days) to be established by further studies could be 
adopted for practical applications.  
Surprisingly, nail poration provided no advantage in multiple dosing experiments. Because of 
the in vitro set up, nail poration could only be performed before mounting the nail clippings in the 
diffusion cells so the effect of multiple nail poration (i.e., as part of the daily application) could 
not be tested. Understanding why nail poration offered no advantage beyond the first dose will 
require further investigation. One line of enquiry is the fate of excipients and active remaining 
inside the nail plate from previous doses and whether these residues could hinder subsequent 
permeation of the active. In addition, the poration device used in this work was developed for skin 
application and provided relatively shallow poration depth and potentially inadequate pore 
geometry (see later, Nile Red experiments). 
The comparison with Trosid® provides additional insights, it was estimated (see materials and 
methods) that approximately 17 times more tioconazole was applied with this formulation than 
with the film-forming L-TIO-C-NC. However, the marketed product delivered only ~7 times more 
drug to the nail than the L-TIO-C-NC lacquer. In other words, the best experimental formulation 
(L-TIO-C-NC) provided increased efficiency of delivery (DRec%) but delivered less drug (TIO-
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Rec) to the nail plate than the marketed product (Table 2). Whether this indicates the need for 
further optimization of the new formulations is debatable as the apparent concentration of 
antifungal in the nail (TIO/Nail values) were above the MIC in all cases (Table 2). Potentially, 
further development and optimization would be required to ensure that drug concentrations exceed 
MIC across the whole nail thickness and the adequate physical status (i.e., free and not crystallized) 
of the drug. Unfortunately, this information is not publicly available for Trosid® and is difficult to 
establish with current experimental methods (Hui et al., 2002, Tudela et al., 2008). 
Figure 2 summarizes the relationship found between IVRT and IVPT data. A trend towards 
increased tioconazole nail delivery (DR%) was observed for vehicles providing extended release 
of the drug (higher [%R24h/%R10h]) despite a lower percentage released in 24 hours. This is best 
illustrated by the film-forming formulation (L-TIO-C-NC) and the control solution (TIO-S). This 
trend suggests a link between the IVPT performance of topical nail formulations and the capacity 
of the vehicle to prevent crystallization and to prolong the time during which the drug is available 
for partitioning and diffusing into the nail plate. Despite their lower drug content, the experimental 
formulations demonstrated similar antifungal activity than Trosid® (Flores et al., 2017) and this 
could be explained by their improved IVRT and IVPT performance. Whilst the in vitro – ex vivo 
relations shown in Figure 2 are far from complete correlations, they demonstrate that optimized 
formulation is a valuable approach to improve ungual drug permeation and the need to develop 
IVRT methods, release criteria, and in vitro - ex vivo correlations specific for these dosage forms.  
3.4 In vitro permeation experiments with Nile Red formulations  
The lipophilic marker, Nile Red, replaced tioconazole in a series of formulations (NR-C-NC, 
NR-NC and L-NR-C-NC) used for LSCM imaging. NR content across the formulations was 0.14 
± 0.01 mg/mL) very close to values expected. All the formulations released NR over 72 h with L-
NR-C-NC and NR-C-NC providing the slowest release, releasing around 40% and 70% at the end 
of experiment time, respectively. 
The distribution of NR throughout the nail was investigated after single and multiple dose nail 
permeation experiments. The x-y planar LSCM images in Figure 3 illustrate the preferential 
localization of the marker at the periphery of the onychocytes, suggesting the intercellular pathway 
to be the favoured route of permeation for Nile Red into the nail. This is consistent with previous 
observations (Chiu et al., 2015) and with the larger lipid content in this the region of the nail plate 
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(Kobayashi et al., 1999). Figure 3B corresponds to a porated nail clipping and the intense 
fluorescence illustrates clearly one of the fissures created which acted, as expected, as reservoir 
for the formulations.  
Transversal images of non-porated nails following multiple dosing with several formulations are 
available in the supplementary material (Fig.S.1). The depth of penetration of NR was measured 
in triplicate and 10 measurements were taken per replicate. The depth of penetration for the marker 
was similar for single and daily applications and unexpectedly, shallower for mechanically porated 
nails (Table 3). Overall, these results are consistent with the IVPT data generated for tioconazole 
(Table 2). The depth of Nile Red penetration ranged from 90 to 160 m across all experiments 
suggesting that the marker had reached only the upper dorsal region of the nail plate. Assuming 
these results can be extrapolated to tioconazole, this would explain why no drug was found in the 
receptor in IVPT. This data signals the need for new routine experimental methods that provide 
the concentration profile of antifungal drugs across the whole nail plate in order to predict in vivo 
performance of formulations and guide rational development. Hui et al. (2002 and 2017) used a 
nail sapling instrument based on a drill that provides the average concentration of the active in the 
“dorsal/intermediate” and the “ventral/intermediate” regions of the nail plate. Finally, Figure 3B 
shows that the fissures created by the dermaroller were rather elongated. Chiu et al. (2015) could 
visualize these “elongated cracks” at least as deep as 32 m into the nails. It could be argued that 
a purpose-made nail poration device that formed narrower but deeper pores would be more 
efficient in enhancing delivery.  
4. Conclusion 
The new nanocapsule-based formulations provided extended release of tioconazole across 
synthetic membranes and this in vitro release capacity was related to their ex vivo performance as 
ungual drug delivery systems and potentially, their antifungal activity previously reported. The 
new film-forming formulation provided the best efficiency of delivery ex vivo and delivered a 
higher percentage of its drug payload than a marketed product. One mechanical nail poration with 
a skin device increased tioconazole delivery to nails in single, but not in multiple dose experiments 
indicating the need for an improved nail poration strategy. Tioconazole nail delivery was 
approximately doubled by daily application of the formulations. Experiments with the fluorescent 
marker Nile Red supported the observations with tioconazole and suggested a penetration depth 
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of 90-160 m attained after 7 days exposure. Overall, the results suggested that judicious 
combination of formulation and nail poration approaches provide a valuable approach to improve 
the performance of ungual drug delivery products. However, further optimization of the 
formulations here presented and of the nail poration strategy are required.  
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Table 1: Characteristics of formulations containing tioconazole (TIO) and Nile Red (NR). NA: 
not applicable; ND: not determined.  
Name Description 
TIO / NR 
concentration 
(mg/mL) 
zeta 
potential PDI 
Mean particle 
size (nm) 
TIO-NC Tioconazole-loaded nanocapsules 
1  -7.2 ± 1.1 0.11±0.03 157±5 
TIO-C-NC Tioconazole-loaded cationic nanocapsules 
1  +15.7 ± 0.8 0.09±0.02 166±4 
L-TIO-C-NC Lacquer containing TIO-C-NC 
1  NA NA 242±12 
TIO-S Ethanol:water solution with TIO 
1  NA NA NA 
L-TIO Lacquer containing TIO-S 
1  NA NA NA 
NR-NC Nile Red-loaded nanocapsules 
0.15  -6.3 ± 0.9 0.13±0.04 132±6 
NR-C-NC Nile-loaded cationic nanocapsules 
0.15  +13.1 ± 0.7 0.15±0.05 141±4 
L-NR-C-NR Lacquer containing NR-C-NC 
0.15  ND ND ND 
NR-S Ethanol:water solution with NR 
0.15  NA NA NA 
Trosid® Commercial lacquer 283  NA NA NA 
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Table 2. IVPT results (mean ±SD, n=3) for the different set-ups tested. D (mg/cm2): Area-
normalized dose of tioconazole applied; N: number of doses applied in multiple dosing 
experiments, TIO-Rec (g) and TIO/nail (g/g) absolute and normalized tioconazole recovered 
from nail samples at the end of experiments, DRec%: percentage recovery with respect to total 
(cumulative) dose applied.  Significant (p<0.05) effect of: *Franz versus in-line cells, porated 
versus intact nail, #multiple versus single dose, in matching experiments. Superscripts (a-q) identify 
pairs of values that are significantly (p<0.05) different. 
Experimental 
conditions   TIO-NC TIO-C-NC TIO-S  L-TIO-C-NC Trosid
® 
Si
ng
le
 d
os
e 
 
Franz 
Intact 
D 5 5 5   
TIO-Rec * , a 1.5 0.6 a,b 3.5 1.0 b 1.2 0.4   
TIO/nail 151 ±58 348 ±101 108 ±42   
DRec% * 0.15 0.06 * 0.35 0.10 * 0.12 0.04   
In-line 
Intact 
D 1.5 1.5 1.5 0.5  
TIO-Rec c 2.9 0.4 2.6 0.09 c,e 1.8 0.2 e 3.6 0.5  
TIO/nail 193 13 228 35 124 9 374 77  
DRec% f 0.96 0.12 g 0.87 0.03 h 0.59 0.08 f,g,h 3.57 0.54  
In-Line 
Porated 
D 1.5 1.5  0.5  
TIO-Rec t,3.5 0.3 u,  4.3 1.0  t,u,  6.9 0.1  
TIO/nail 345 ±95 446 ±102  347 ±32  
DRec% v 1.16 0.10 w,  1.42 0.33  v, w,   6.89 0.12  
D
ai
ly
 d
os
in
g 
In-Line 
Intact 
D x N 1.5 x 7 1.5 x 7 1.5 x 7 0.5 x 7 4.25 x 14 
TIO-Rec #, i 4.6 ±0.1 #, j 6.2 ±1.7 k 2.6 ±0.4 #, l 8.8 2.8 i,j,k,l  60.4 ±12.9 
TIO/nail 438 ±176 555 ±177 248 ±30 550 ±123 5815 ±1639 
DRec% #,m 0.222x10-3 #,n 0.30 0.08 #,p 0.12 0.02 #,m,n,p,q 1.25 0.40 q 0.51 0.11 
In-Line 
Porated 
D x N 1.5 x 7 1.5 x 7  0.5 x 7  
TIO-Rec 5.3 1.3 # 7.7 0.6  8.3 ±3.3  
TIO/nail 345 ±27 602 ±197  446 ± 32  
DRec% #, r 0.25  0.06 #, s 0.37 0.03  #, r,s 1.18 0.45  
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Table 3. Mean (±SD, n=3) penetration depth (µm) of Nile Red into the nail plate after 7 days 
IVPT. The formulations were applied either as single dose at time zero on intact nails, or as 
multiple, daily doses on intact and porated nails. Superscripts identify pairs of values that are 
significantly (p<0.05) different. 
Protocol L-NR-C-NC NR-C-NC NR-NC NR-S 
Single/Intact - # 146 ± 9 131 ± 7 163 ± 7 
Daily/Intact 122 ± 17 # , 127 ± 5 103 ± 26 131 ± 28 
Daily/Porated 98 ± 27  93 ± 12 97 ± 9 120 ± 26 
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Figure 1. A) IVRT results: Mean percentage (SD, n=3) tioconazole released from experimental 
formulations and Trosid® across silicone membrane. B) IVRT ratios [%R24h/%R2h] and 
[%R24h/%R10h] determined from IVRT data. Symbols: [a] = value different to [%R24h/%R2h] for 
[TIO-S]; [b] value different to [%R24h/%R2h] for [TIO-S] and Trosid®; [c] = value different to 
[%R24h/%R10h] for [TIO-S], [L-TIO] and Trosid®. C) IVPT results: Mean (SD, n=3) percentage 
tioconazole recovery from intact nail clippings (DRec%) at the end of the 7 days – multiple dosing 
experiments with respect to the total dose applied. Symbols: [d] value significantly different to 
DRec% for L-TIO-C-NC. 
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Figure 2: Relationship between in vitro release (IVRT) and ex vivo (IVPT) performance of the 
formulations. The ex vivo performance is characterized by DRec% or percentage of total amount 
of tioconazole applied that is recovered from nail clippings after 7 days, multiple dosing IVPT. 
The in vitro release performance is characterized by the percentage released after 24h (top panel) 
and the [%R24h/%R10h] ratio determined in IVRT conditions. All values are mean SD (n=3). 
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Figure 3. Planar images (x-y) at a ~ 20 µm depth of (A) an intact nail and (B) a porated nail 
showing Nile Red disposition following a 7 days experiment involving daily application of the 
NR-S formulation. Scale bar = 50 µm. 
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Supplementary material 
 
 
Supplementary Fig.S-1. Representative images of 3 transversally sectioned intact nails following 
a 7 day treatment with: (1) L-NR-C-NC; (2) NR-C-NC; (3) NR-NC; (4) NR-S.: (A) optical 
micrographs of the nail, (B) optical and NR fluorescent images merged, (C) NR fluorescence. 
Scale bar = 100 µm. 
